Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Carlsmed (CARL) EBITDA (2024 - 2025)

Carlsmed (CARL) has disclosed EBITDA for 2 consecutive years, with -$8.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 82.48% year-over-year to -$8.6 million, compared with a TTM value of -$29.1 million through Dec 2025, changed N/A, and an annual FY2025 reading of -$29.6 million, down 22.17% over the prior year.
  • EBITDA was -$8.6 million for Q4 2025 at Carlsmed, up from -$9.0 million in the prior quarter.
  • Across five years, EBITDA topped out at -$4.7 million in Q4 2024 and bottomed at -$9.0 million in Q3 2025.